Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Circulating Receptor Activator of Nuclear Factor-κB (RANK), RANK ligand (RANKL) and Mammographic Density in Premenopausal Women.

Toriola AT, Appleton CM, Zong X, Luo J, Weilbaecher K, Tamimi RM, Colditz GA.

Cancer Prev Res (Phila). 2018 Oct 23. pii: canprevres.0199.2018. doi: 10.1158/1940-6207.CAPR-18-0199. [Epub ahead of print]

PMID:
30352839
2.

Inhibition of the Stromal p38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone Loss.

Murali B, Ren Q, Luo X, Faget DV, Wang C, Johnson RM, Gruosso T, Flanagan KC, Fu Y, Leahy K, Alspach E, Su X, Ross MH, Burnette B, Weilbaecher KN, Park M, Mbalaviele G, Monahan JB, Stewart SA.

Cancer Res. 2018 Oct 1;78(19):5618-5630. doi: 10.1158/0008-5472.CAN-18-0234. Epub 2018 Aug 9.

PMID:
30093561
3.

The β3-integrin endothelial adhesome regulates microtubule-dependent cell migration.

Atkinson SJ, Gontarczyk AM, Alghamdi AA, Ellison TS, Johnson RT, Fowler WJ, Kirkup BM, Silva BC, Harry BE, Schneider JG, Weilbaecher KN, Mogensen MM, Bass MD, Parsons M, Edwards DR, Robinson SD.

EMBO Rep. 2018 Jul;19(7). pii: e44578. doi: 10.15252/embr.201744578. Epub 2018 May 24.

4.

Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.

Pernas S, Martin M, Kaufman PA, Gil-Martin M, Gomez Pardo P, Lopez-Tarruella S, Manso L, Ciruelos E, Perez-Fidalgo JA, Hernando C, Ademuyiwa FO, Weilbaecher K, Mayer I, Pluard TJ, Martinez Garcia M, Vahdat L, Perez-Garcia J, Wach A, Barker D, Fung S, Romagnoli B, Cortes J.

Lancet Oncol. 2018 Jun;19(6):812-824. doi: 10.1016/S1470-2045(18)30147-5. Epub 2018 Apr 26.

PMID:
29706375
5.

Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance.

Meyer MA, Baer JM, Knolhoff BL, Nywening TM, Panni RZ, Su X, Weilbaecher KN, Hawkins WG, Ma C, Fields RC, Linehan DC, Challen GA, Faccio R, Aft RL, DeNardo DG.

Nat Commun. 2018 Mar 28;9(1):1250. doi: 10.1038/s41467-018-03600-6.

6.

Radionuclides transform chemotherapeutics into phototherapeutics for precise treatment of disseminated cancer.

Kotagiri N, Cooper ML, Rettig M, Egbulefu C, Prior J, Cui G, Karmakar P, Zhou M, Yang X, Sudlow G, Marsala L, Chanswangphuwana C, Lu L, Habimana-Griffin L, Shokeen M, Xu X, Weilbaecher K, Tomasson M, Lanza G, DiPersio JF, Achilefu S.

Nat Commun. 2018 Jan 18;9(1):275. doi: 10.1038/s41467-017-02758-9.

7.

Perfusion-based fluorescence imaging method delineates diverse organs and identifies multifocal tumors using generic near-infrared molecular probes.

Miller J, Wang ST, Orukari I, Prior J, Sudlow G, Su X, Liang K, Tang R, Hillman EMC, Weilbaecher KN, Culver JP, Berezin MY, Achilefu S.

J Biophotonics. 2018 Apr;11(4):e201700232. doi: 10.1002/jbio.201700232. Epub 2018 Jan 3.

PMID:
29206348
8.

HTLV-1 viral oncogene HBZ induces osteolytic bone disease in transgenic mice.

Esser AK, Rauch DA, Xiang J, Harding JC, Kohart NA, Ross MH, Su X, Wu K, Huey D, Xu Y, Vij K, Green PL, Rosol TJ, Niewiesk S, Ratner L, Weilbaecher KN.

Oncotarget. 2017 Aug 27;8(41):69250-69263. doi: 10.18632/oncotarget.20565. eCollection 2017 Sep 19.

9.

Bone-Induced Expression of Integrin β3 Enables Targeted Nanotherapy of Breast Cancer Metastases.

Ross MH, Esser AK, Fox GC, Schmieder AH, Yang X, Hu G, Pan D, Su X, Xu Y, Novack DV, Walsh T, Colditz GA, Lukaszewicz GH, Cordell E, Novack J, Fitzpatrick JAJ, Waning DL, Mohammad KS, Guise TA, Lanza GM, Weilbaecher KN.

Cancer Res. 2017 Nov 15;77(22):6299-6312. doi: 10.1158/0008-5472.CAN-17-1225. Epub 2017 Aug 30.

10.

Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians.

Ademuyiwa FO, Tao Y, Luo J, Weilbaecher K, Ma CX.

Breast Cancer Res Treat. 2017 Feb;161(3):491-499. doi: 10.1007/s10549-016-4062-y. Epub 2016 Dec 3.

11.

Evaluating Acetate Metabolism for Imaging and Targeting in Multiple Myeloma.

Fontana F, Ge X, Su X, Hathi D, Xiang J, Cenci S, Civitelli R, Shoghi KI, Akers WJ, D'avignon A, Weilbaecher KN, Shokeen M.

Clin Cancer Res. 2017 Jan 15;23(2):416-429. doi: 10.1158/1078-0432.CCR-15-2134. Epub 2016 Aug 2.

12.

Antagonizing Integrin β3 Increases Immunosuppression in Cancer.

Su X, Esser AK, Amend SR, Xiang J, Xu Y, Ross MH, Fox GC, Kobayashi T, Steri V, Roomp K, Fontana F, Hurchla MA, Knolhoff BL, Meyer MA, Morgan EA, Tomasson JC, Novack JS, Zou W, Faccio R, Novack DV, Robinson SD, Teitelbaum SL, DeNardo DG, Schneider JG, Weilbaecher KN.

Cancer Res. 2016 Jun 15;76(12):3484-95. doi: 10.1158/0008-5472.CAN-15-2663. Epub 2016 May 23.

13.

Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer.

D'Amico L, Mahajan S, Capietto AH, Yang Z, Zamani A, Ricci B, Bumpass DB, Meyer M, Su X, Wang-Gillam A, Weilbaecher K, Stewart SA, DeNardo DG, Faccio R.

J Exp Med. 2016 May 2;213(5):827-40. doi: 10.1084/jem.20150950. Epub 2016 Apr 4.

14.

Stromal-Initiated Changes in the Bone Promote Metastatic Niche Development.

Luo X, Fu Y, Loza AJ, Murali B, Leahy KM, Ruhland MK, Gang M, Su X, Zamani A, Shi Y, Lavine KJ, Ornitz DM, Weilbaecher KN, Long F, Novack DV, Faccio R, Longmore GD, Stewart SA.

Cell Rep. 2016 Jan 5;14(1):82-92. doi: 10.1016/j.celrep.2015.12.016. Epub 2015 Dec 24.

15.

Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials.

Kroep JR, Charehbili A, Coleman RE, Aft RL, Hasegawa Y, Winter MC, Weilbaecher K, Akazawa K, Hinsley S, Putter H, Liefers GJ, Nortier JWR, Kohno N.

Eur J Cancer. 2016 Feb;54:57-63. doi: 10.1016/j.ejca.2015.10.011. Epub 2015 Dec 23.

16.

Dual-therapy with αvβ3-targeted Sn2 lipase-labile fumagillin-prodrug nanoparticles and zoledronic acid in the Vx2 rabbit tumor model.

Esser AK, Schmieder AH, Ross MH, Xiang J, Su X, Cui G, Zhang H, Yang X, Allen JS, Williams T, Wickline SA, Pan D, Lanza GM, Weilbaecher KN.

Nanomedicine. 2016 Jan;12(1):201-11. doi: 10.1016/j.nano.2015.10.003. Epub 2015 Oct 27.

17.

Contact-facilitated drug delivery with Sn2 lipase labile prodrugs optimize targeted lipid nanoparticle drug delivery.

Pan D, Pham CT, Weilbaecher KN, Tomasson MH, Wickline SA, Lanza GM.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016 Jan-Feb;8(1):85-106. doi: 10.1002/wnan.1355. Epub 2015 Aug 21. Review.

18.

CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer.

Xiang J, Hurchla MA, Fontana F, Su X, Amend SR, Esser AK, Douglas GJ, Mudalagiriyappa C, Luker KE, Pluard T, Ademuyiwa FO, Romagnoli B, Tuffin G, Chevalier E, Luker GD, Bauer M, Zimmermann J, Aft RL, Dembowsky K, Weilbaecher KN.

Mol Cancer Ther. 2015 Nov;14(11):2473-85. doi: 10.1158/1535-7163.MCT-15-0252. Epub 2015 Aug 12.

19.

Suppression of β3-integrin in mice triggers a neuropilin-1-dependent change in focal adhesion remodelling that can be targeted to block pathological angiogenesis.

Ellison TS, Atkinson SJ, Steri V, Kirkup BM, Preedy ME, Johnson RT, Ruhrberg C, Edwards DR, Schneider JG, Weilbaecher K, Robinson SD.

Dis Model Mech. 2015 Sep;8(9):1105-19. doi: 10.1242/dmm.019927. Epub 2015 Jul 9.

20.

Whole Genome Sequence of Multiple Myeloma-Prone C57BL/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell Types.

Amend SR, Wilson WC, Chu L, Lu L, Liu P, Serie D, Su X, Xu Y, Wang D, Gramolini A, Wen XY, O'Neal J, Hurchla M, Vachon CM, Colditz G, Vij R, Weilbaecher KN, Tomasson MH.

PLoS One. 2015 May 28;10(5):e0127828. doi: 10.1371/journal.pone.0127828. eCollection 2015.

21.

Small Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma.

Soodgupta D, Pan D, Cui G, Senpan A, Yang X, Lu L, Weilbaecher KN, Prochownik EV, Lanza GM, Tomasson MH.

Mol Cancer Ther. 2015 Jun;14(6):1286-1294. doi: 10.1158/1535-7163.MCT-14-0774-T. Epub 2015 Mar 30.

22.

Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer.

Junankar S, Shay G, Jurczyluk J, Ali N, Down J, Pocock N, Parker A, Nguyen A, Sun S, Kashemirov B, McKenna CE, Croucher PI, Swarbrick A, Weilbaecher K, Phan TG, Rogers MJ.

Cancer Discov. 2015 Jan;5(1):35-42. doi: 10.1158/2159-8290.CD-14-0621. Epub 2014 Oct 13.

23.

Thrombospondin-1 regulates bone homeostasis through effects on bone matrix integrity and nitric oxide signaling in osteoclasts.

Amend SR, Uluckan O, Hurchla M, Leib D, Novack DV, Silva M, Frazier W, Weilbaecher KN.

J Bone Miner Res. 2015 Jan;30(1):106-15. doi: 10.1002/jbmr.2308.

24.

Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma.

Sanfilippo KM, Gage B, Luo S, Weilbaecher K, Tomasson M, Vij R, Colditz G, Carson K.

Leuk Lymphoma. 2015 Mar;56(3):615-21. doi: 10.3109/10428194.2014.924117. Epub 2014 Jul 14.

25.

A randomized phase II trial investigating the effect of platelet function inhibition on circulating tumor cells in patients with metastatic breast cancer.

Roop RP, Naughton MJ, Van Poznak C, Schneider JG, Lammers PE, Pluard TJ, Johnson F, Eby CS, Weilbaecher KN.

Clin Breast Cancer. 2013 Dec;13(6):409-15. doi: 10.1016/j.clbc.2013.08.006.

26.

Acute depletion of endothelial β3-integrin transiently inhibits tumor growth and angiogenesis in mice.

Steri V, Ellison TS, Gontarczyk AM, Weilbaecher K, Schneider JG, Edwards D, Fruttiger M, Hodivala-Dilke KM, Robinson SD.

Circ Res. 2014 Jan 3;114(1):79-91. doi: 10.1161/CIRCRESAHA.114.301591. Epub 2013 Oct 8.

PMID:
24103390
27.

Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myeloma.

Soodgupta D, Hurchla MA, Jiang M, Zheleznyak A, Weilbaecher KN, Anderson CJ, Tomasson MH, Shokeen M.

PLoS One. 2013;8(2):e55841. doi: 10.1371/journal.pone.0055841. Epub 2013 Feb 8. Erratum in: PLoS One. 2013;8(8). doi:10.1371/annotation/8532e291-73d3-461c-810d-0533ccb1eba0.

28.

Role of WNT7B-induced noncanonical pathway in advanced prostate cancer.

Zheng D, Decker KF, Zhou T, Chen J, Qi Z, Jacobs K, Weilbaecher KN, Corey E, Long F, Jia L.

Mol Cancer Res. 2013 May;11(5):482-93. doi: 10.1158/1541-7786.MCR-12-0520. Epub 2013 Feb 5.

29.

Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation.

Yang C, Davis JL, Zeng R, Vora P, Su X, Collins LI, Vangveravong S, Mach RH, Piwnica-Worms D, Weilbaecher KN, Faccio R, Novack DV.

Cancer Discov. 2013 Feb;3(2):212-23. doi: 10.1158/2159-8290.CD-12-0271. Epub 2012 Dec 26.

30.

Hedgehog-targeted therapeutics uncouple the vicious cycle of bone metastasis.

Hurchla MA, Weilbaecher KN.

Oncoimmunology. 2012 Nov 1;1(8):1411-1413.

31.

Noncompetitive modulation of the proteasome by imidazoline scaffolds overcomes bortezomib resistance and delays MM tumor growth in vivo.

Lansdell TA, Hurchla MA, Xiang J, Hovde S, Weilbaecher KN, Henry RW, Tepe JJ.

ACS Chem Biol. 2013 Mar 15;8(3):578-87. doi: 10.1021/cb300568r. Epub 2012 Dec 11.

32.

The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling.

Su X, Floyd DH, Hughes A, Xiang J, Schneider JG, Uluckan O, Heller E, Deng H, Zou W, Craft CS, Wu K, Hirbe AC, Grabowska D, Eagleton MC, Townsley S, Collins L, Piwnica-Worms D, Steinberg TH, Novack DV, Conley PB, Hurchla MA, Rogers M, Weilbaecher KN.

J Clin Invest. 2012 Oct;122(10):3579-92. doi: 10.1172/JCI38576. Epub 2012 Sep 17.

33.

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.

Hurchla MA, Garcia-Gomez A, Hornick MC, Ocio EM, Li A, Blanco JF, Collins L, Kirk CJ, Piwnica-Worms D, Vij R, Tomasson MH, Pandiella A, San Miguel JF, Garayoa M, Weilbaecher KN.

Leukemia. 2013 Feb;27(2):430-40. doi: 10.1038/leu.2012.183. Epub 2012 Jul 5.

34.

Breast cancer cell targeting by prenylation inhibitors elucidated in living animals with a bioluminescence reporter.

Chinault SL, Prior JL, Kaltenbronn KM, Penly A, Weilbaecher KN, Piwnica-Worms D, Blumer KJ.

Clin Cancer Res. 2012 Aug 1;18(15):4136-44. doi: 10.1158/1078-0432.CCR-12-0642. Epub 2012 Jun 12.

35.

Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer.

Aft RL, Naughton M, Trinkaus K, Weilbaecher K.

Br J Cancer. 2012 Jun 26;107(1):7-11. doi: 10.1038/bjc.2012.210. Epub 2012 May 22.

36.

Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment.

Heller E, Hurchla MA, Xiang J, Su X, Chen S, Schneider J, Joeng KS, Vidal M, Goldberg L, Deng H, Hornick MC, Prior JL, Piwnica-Worms D, Long F, Cagan R, Weilbaecher KN.

Cancer Res. 2012 Feb 15;72(4):897-907. doi: 10.1158/0008-5472.CAN-11-2681. Epub 2011 Dec 20.

37.

Integrin α(v)β₃ as a PET imaging biomarker for osteoclast number in mouse models of negative and positive osteoclast regulation.

Zheleznyak A, Wadas TJ, Sherman CD, Wilson JM, Kostenuik PJ, Weilbaecher KN, Anderson CJ.

Mol Imaging Biol. 2012 Aug;14(4):500-8. doi: 10.1007/s11307-011-0512-4.

38.

CD8+ T cells regulate bone tumor burden independent of osteoclast resorption.

Zhang K, Kim S, Cremasco V, Hirbe AC, Collins L, Piwnica-Worms D, Novack DV, Weilbaecher K, Faccio R.

Cancer Res. 2011 Jul 15;71(14):4799-808. doi: 10.1158/0008-5472.CAN-10-3922. Epub 2011 May 20. Erratum in: Cancer Res. 2012 Jan 15;72(2):568.

39.

Cancer to bone: a fatal attraction.

Weilbaecher KN, Guise TA, McCauley LK.

Nat Rev Cancer. 2011 Jun;11(6):411-25. doi: 10.1038/nrc3055. Epub 2011 May 19. Review.

40.

The ARF tumor suppressor regulates bone remodeling and osteosarcoma development in mice.

Rauch DA, Hurchla MA, Harding JC, Deng H, Shea LK, Eagleton MC, Niewiesk S, Lairmore MD, Piwnica-Worms D, Rosol TJ, Weber JD, Ratner L, Weilbaecher KN.

PLoS One. 2010 Dec 30;5(12):e15755. doi: 10.1371/journal.pone.0015755.

41.

Integrins and bone metastasis: integrating tumor cell and stromal cell interactions.

Schneider JG, Amend SR, Weilbaecher KN.

Bone. 2011 Jan;48(1):54-65. doi: 10.1016/j.bone.2010.09.016. Epub 2010 Sep 17. Review.

42.

A role for the epithelial microenvironment at tumor boundaries: evidence from Drosophila and human squamous cell carcinomas.

Vidal M, Salavaggione L, Ylagan L, Wilkins M, Watson M, Weilbaecher K, Cagan R.

Am J Pathol. 2010 Jun;176(6):3007-14. doi: 10.2353/ajpath.2010.090253. Epub 2010 Apr 2.

43.

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.

Aft R, Naughton M, Trinkaus K, Watson M, Ylagan L, Chavez-MacGregor M, Zhai J, Kuo S, Shannon W, Diemer K, Herrmann V, Dietz J, Ali A, Ellis M, Weiss P, Eberlein T, Ma C, Fracasso PM, Zoberi I, Taylor M, Gillanders W, Pluard T, Mortimer J, Weilbaecher K.

Lancet Oncol. 2010 May;11(5):421-8. doi: 10.1016/S1470-2045(10)70054-1. Epub 2010 Mar 31.

44.

The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases?

Hirbe AC, Morgan EA, Weilbaecher KN.

Curr Pharm Des. 2010;16(11):1284-90. Review.

PMID:
20166978
45.

A gene expression signature that predicts the therapeutic response of the basal-like breast cancer to neoadjuvant chemotherapy.

Lin Y, Lin S, Watson M, Trinkaus KM, Kuo S, Naughton MJ, Weilbaecher K, Fleming TP, Aft RL.

Breast Cancer Res Treat. 2010 Oct;123(3):691-9. doi: 10.1007/s10549-009-0664-y. Epub 2009 Dec 6.

46.

Dissection of platelet and myeloid cell defects by conditional targeting of the beta3-integrin subunit.

Morgan EA, Schneider JG, Baroni TE, Uluçkan O, Heller E, Hurchla MA, Deng H, Floyd D, Berdy A, Prior JL, Piwnica-Worms D, Teitelbaum SL, Ross FP, Weilbaecher KN.

FASEB J. 2010 Apr;24(4):1117-27. doi: 10.1096/fj.09-138420. Epub 2009 Nov 20.

47.

Targeting the alphavbeta3 integrin for small-animal PET/CT of osteolytic bone metastases.

Wadas TJ, Deng H, Sprague JE, Zheleznyak A, Weilbaecher KN, Anderson CJ.

J Nucl Med. 2009 Nov;50(11):1873-80. doi: 10.2967/jnumed.109.067140.

48.

The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts.

Hirbe AC, Roelofs AJ, Floyd DH, Deng H, Becker SN, Lanigan LG, Apicelli AJ, Xu Z, Prior JL, Eagleton MC, Piwnica-Worms D, Rogers MJ, Weilbaecher K.

Bone. 2009 May;44(5):908-16. doi: 10.1016/j.bone.2009.01.010. Epub 2009 Jan 23.

49.

CD47 regulates bone mass and tumor metastasis to bone.

Uluçkan O, Becker SN, Deng H, Zou W, Prior JL, Piwnica-Worms D, Frazier WA, Weilbaecher KN.

Cancer Res. 2009 Apr 1;69(7):3196-204. doi: 10.1158/0008-5472.CAN-08-3358. Epub 2009 Mar 10.

50.

Interferon-gamma targets cancer cells and osteoclasts to prevent tumor-associated bone loss and bone metastases.

Xu Z, Hurchla MA, Deng H, Uluçkan O, Bu F, Berdy A, Eagleton MC, Heller EA, Floyd DH, Dirksen WP, Shu S, Tanaka Y, Fernandez SA, Rosol TJ, Weilbaecher KN.

J Biol Chem. 2009 Feb 13;284(7):4658-66. doi: 10.1074/jbc.M804812200. Epub 2008 Dec 5.

Supplemental Content

Loading ...
Support Center